메뉴 건너뛰기




Volumn 82, Issue 2, 2011, Pages 139-147

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment

Author keywords

Iron depletion; Ovarian cancer; Primary cultures; Screening

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; IRON; IRON CHELATING AGENT; UNCLASSIFIED DRUG; VLX 50;

EID: 79958132098     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.04.003     Document Type: Article
Times cited : (14)

References (45)
  • 2
    • 17044373269 scopus 로고    scopus 로고
    • Finding the target after screening the phenotype
    • C.P. Hart Finding the target after screening the phenotype Drug Discov Today 10 2005 513 519
    • (2005) Drug Discov Today , vol.10 , pp. 513-519
    • Hart, C.P.1
  • 3
    • 0000356151 scopus 로고    scopus 로고
    • A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening
    • S. Dhar, J. Gullbo, K. Nilsson, P. Nygren, and R. Larsson A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening J Biomol Screen 3 1998 207 215
    • (1998) J Biomol Screen , vol.3 , pp. 207-215
    • Dhar, S.1    Gullbo, J.2    Nilsson, K.3    Nygren, P.4    Larsson, R.5
  • 4
    • 77949957365 scopus 로고    scopus 로고
    • Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
    • S.V. Sharma, D.A. Haber, and J. Settleman Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat Rev Cancer 10 2010 241 253
    • (2010) Nat Rev Cancer , vol.10 , pp. 241-253
    • Sharma, S.V.1    Haber, D.A.2    Settleman, J.3
  • 5
    • 59149093636 scopus 로고    scopus 로고
    • Chemosensitivity and chemoresistance testing in ovarian cancer
    • I.A. Cree Chemosensitivity and chemoresistance testing in ovarian cancer Curr Opin Obstet Gynecol 21 2009 39 43
    • (2009) Curr Opin Obstet Gynecol , vol.21 , pp. 39-43
    • Cree, I.A.1
  • 6
    • 67749139054 scopus 로고    scopus 로고
    • Predictive tests for individualization of pharmacological cancer treatment
    • P. Nygren, and R. Larsson Predictive tests for individualization of pharmacological cancer treatment Expert Opin Med Diagn 2 2008 1 12
    • (2008) Expert Opin Med Diagn , vol.2 , pp. 1-12
    • Nygren, P.1    Larsson, R.2
  • 7
    • 0033105697 scopus 로고    scopus 로고
    • Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic
    • DOI 10.1016/S0959-8049(98)00286-X, PII S095980499800286X
    • H. Fridborg, E. Jonsson, P. Nygren, and R. Larsson Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic Eur J Cancer 35 1999 424 432 (Pubitemid 29151940)
    • (1999) European Journal of Cancer , vol.35 , Issue.3 , pp. 424-432
    • Fridborg, H.1    Jonsson, E.2    Nygren, P.3    Larsson, R.4
  • 9
    • 42549086712 scopus 로고    scopus 로고
    • The novel alkylating prodrug J1: Diagnosis directed activity profile ex vivo and combination analyses in vitro
    • DOI 10.1007/s10637-007-9092-1
    • M. Wickstrom, C. Haglund, H. Lindman, P. Nygren, R. Larsson, and J. Gullbo The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro Invest New Drugs 26 2008 195 204 (Pubitemid 351579681)
    • (2008) Investigational New Drugs , vol.26 , Issue.3 , pp. 195-204
    • Wickstrom, M.1    Haglund, C.2    Lindman, H.3    Nygren, P.4    Larsson, R.5    Gullbo, J.6
  • 10
    • 0021883048 scopus 로고
    • Application of a human tumor colony-forming assay to new drug screening
    • R.H. Shoemaker, M.K. Wolpert-DeFilippes, D.H. Kern, M.M. Lieber, R.W. Makuch, and N.R. Melnick Application of a human tumor colony-forming assay to new drug screening Cancer Res 45 1985 2145 2153 (Pubitemid 15024321)
    • (1985) Cancer Research , vol.45 , Issue.5 , pp. 2145-2153
    • Shoemaker, R.H.1    Wolpert-DeFilippes, M.K.2    Kern, D.H.3
  • 11
    • 77955069305 scopus 로고    scopus 로고
    • High-throughput screening of natural products for cancer therapy
    • Harvey AL, Cree IA. High-throughput screening of natural products for cancer therapy. Planta Med 76:1080-6.
    • Planta Med , vol.76 , pp. 1080-1086
    • Harvey, A.L.1    Cree, I.A.2
  • 12
    • 77955275498 scopus 로고    scopus 로고
    • Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue
    • Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10:375-9.
    • Curr Opin Pharmacol , vol.10 , pp. 375-379
    • Cree, I.A.1    Glaysher, S.2    Harvey, A.L.3
  • 13
    • 1842336815 scopus 로고    scopus 로고
    • In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
    • DOI 10.1002/(SICI)1097-0215(19970917)72:6<1008::AID-IJC15>3.0.CO;2- 0
    • K. Csoka, B. Tholander, E. Gerdin, M. de la Torre, R. Larsson, and P. Nygren In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 72 1997 1008 1012 (Pubitemid 27433566)
    • (1997) International Journal of Cancer , vol.72 , Issue.6 , pp. 1008-1012
    • Csoka, K.1    Tholander, B.2    Gerdin, E.3    De La Torre, M.4    Larsson, R.5    Nygren, P.6
  • 14
    • 0026529184 scopus 로고
    • Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)
    • R. Larsson, J. Kristensen, C. Sandberg, and P. Nygren Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 50 1992 177 185
    • (1992) Int J Cancer , vol.50 , pp. 177-185
    • Larsson, R.1    Kristensen, J.2    Sandberg, C.3    Nygren, P.4
  • 15
    • 0028059914 scopus 로고
    • Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)
    • DOI 10.1006/gyno.1994.1187
    • K. Csoka, R. Larsson, B. Tholander, E. Gerdin, M. de la Torre, and P. Nygren Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA) Gynecol Oncol 54 1994 163 170 (Pubitemid 24256464)
    • (1994) Gynecologic Oncology , vol.54 , Issue.2 , pp. 163-170
    • Csoka, K.1    Larsson, R.2    Tholander, B.3    Gerdin, E.4    De La Torre, M.5    Nygren, P.6
  • 16
    • 50349098488 scopus 로고    scopus 로고
    • The fluorometric microculture cytotoxicity assay
    • E. Lindhagen, P. Nygren, and R. Larsson The fluorometric microculture cytotoxicity assay Nat Protoc 3 2008 1364 1369
    • (2008) Nat Protoc , vol.3 , pp. 1364-1369
    • Lindhagen, E.1    Nygren, P.2    Larsson, R.3
  • 19
    • 18044370285 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model
    • DOI 10.1016/j.ejps.2005.02.006
    • L.E. Friberg, S.B. Hassan, E. Lindhagen, R. Larsson, and M.O. Karlsson Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model Eur J Pharm Sci 25 2005 163 173 (Pubitemid 40602206)
    • (2005) European Journal of Pharmaceutical Sciences , vol.25 , Issue.1 , pp. 163-173
    • Friberg, L.E.1    Hassan, S.B.2    Lindhagen, E.3    Larsson, R.4    Karlsson, M.O.5
  • 20
    • 0033653660 scopus 로고    scopus 로고
    • Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats
    • E. Jonsson, L.E. Friberg, M.O. Karlsson, S.B. Hassan, A. Freijs, and K. Hansen Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats Cancer Chemother Pharmacol 46 2000 493 500
    • (2000) Cancer Chemother Pharmacol , vol.46 , pp. 493-500
    • Jonsson, E.1    Friberg, L.E.2    Karlsson, M.O.3    Hassan, S.B.4    Freijs, A.5    Hansen, K.6
  • 21
    • 0023792919 scopus 로고
    • Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
    • D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, and T.H. Nofziger Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines Cancer Res 48 1988 4827 4833
    • (1988) Cancer Res , vol.48 , pp. 4827-4833
    • Scudiero, D.A.1    Shoemaker, R.H.2    Paull, K.D.3    Monks, A.4    Tierney, S.5    Nofziger, T.H.6
  • 23
    • 0033003760 scopus 로고    scopus 로고
    • A simple statistical parameter for use in evaluation and validation of high throughput screening assays
    • DOI 10.1177/108705719900400206
    • J.H. Zhang, T.D. Chung, and K.R. Oldenburg A simple statistical parameter for use in evaluation and validation of high throughput screening assays J Biomol Screen 4 1999 67 73 (Pubitemid 29278954)
    • (1999) Journal of Biomolecular Screening , vol.4 , Issue.2 , pp. 67-73
    • Zhang, J.-H.1    Chung, T.D.Y.2    Oldenburg, K.R.3
  • 24
    • 54249090796 scopus 로고    scopus 로고
    • Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
    • E. Lindhagen, A. Eriksson, M. Wickstrom, K. Danielsson, B. Grundmark, and R. Henriksson Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia Eur J Haematol 81 2008 344 353
    • (2008) Eur J Haematol , vol.81 , pp. 344-353
    • Lindhagen, E.1    Eriksson, A.2    Wickstrom, M.3    Danielsson, K.4    Grundmark, B.5    Henriksson, R.6
  • 25
    • 70449466605 scopus 로고    scopus 로고
    • Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells
    • Y. Eberhard, S.P. McDermott, X. Wang, M. Gronda, A. Venugopal, and T.E. Wood Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells Blood 114 2009 3064 3073
    • (2009) Blood , vol.114 , pp. 3064-3073
    • Eberhard, Y.1    McDermott, S.P.2    Wang, X.3    Gronda, M.4    Venugopal, A.5    Wood, T.E.6
  • 26
    • 67349137868 scopus 로고    scopus 로고
    • Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents
    • D.R. Richardson, D.S. Kalinowski, S. Lau, P.J. Jansson, and D.B. Lovejoy Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents Biochim Biophys Acta 1790 2009 702 717
    • (2009) Biochim Biophys Acta , vol.1790 , pp. 702-717
    • Richardson, D.R.1    Kalinowski, D.S.2    Lau, S.3    Jansson, P.J.4    Lovejoy, D.B.5
  • 27
    • 64549140743 scopus 로고    scopus 로고
    • Two-step spin-transition iron(III) compound with a wide [High Spin-Low Spin] plateau
    • J. Tang, J. Costa, S. Smulders, G. Molnár, A. Bousseksou, and S. Teat Two-step spin-transition iron(III) compound with a wide [High Spin-Low Spin] plateau Inorg Chem 48 2009 2128 2135
    • (2009) Inorg Chem , vol.48 , pp. 2128-2135
    • Tang, J.1    Costa, J.2    Smulders, S.3    Molnár, G.4    Bousseksou, A.5    Teat, S.6
  • 31
    • 0141566685 scopus 로고    scopus 로고
    • Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
    • T. Voskoglou-Nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 2003 4227 4239 (Pubitemid 37204044)
    • (2003) Clinical Cancer Research , vol.9 , Issue.11 , pp. 4227-4239
    • Voskoglou-Nomikos, T.1    Pater, J.L.2    Seymour, L.3
  • 32
    • 1942518907 scopus 로고    scopus 로고
    • The hollow fibre model in cancer drug screening: The NCI experience
    • DOI 10.1016/j.ejca.2003.11.029, PII S0959804904000115
    • S. Decker, M. Hollingshead, C.A. Bonomi, J.P. Carter, and E.A. Sausville The hollow fibre model in cancer drug screening: the NCI experience Eur J Cancer 40 2004 821 826 (Pubitemid 38519760)
    • (2004) European Journal of Cancer , vol.40 , Issue.6 , pp. 821-826
    • Decker, S.1    Hollingshead, M.2    Bonomi, C.A.3    Carter, J.P.4    Sausville, E.A.5
  • 33
    • 34250778335 scopus 로고    scopus 로고
    • Future of toxicology - Iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy
    • DOI 10.1021/tx700039c
    • D.S. Kalinowski, and D.R. Richardson Future of toxicology - iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy Chem Res Toxicol 20 2007 715 720 (Pubitemid 46953677)
    • (2007) Chemical Research in Toxicology , vol.20 , Issue.5 , pp. 715-720
    • Kalinowski, D.S.1    Richardson, D.R.2
  • 34
    • 33745823841 scopus 로고    scopus 로고
    • Ribonucleotide reductase inhibitors and future drug design
    • DOI 10.2174/156800906777723949
    • J. Shao, B. Zhou, B. Chu, and Y. Yen Ribonucleotide reductase inhibitors and future drug design Curr Cancer Drug Targets 6 2006 409 431 (Pubitemid 44033390)
    • (2006) Current Cancer Drug Targets , vol.6 , Issue.5 , pp. 409-431
    • Shao, J.1    Zhou, B.2    Chu, B.3    Yen, Y.4
  • 35
    • 0014962872 scopus 로고
    • Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas
    • H.L. Elford, M. Freese, E. Passamani, and H.P. Morris Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas J Biol Chem 245 1970 5228 5233
    • (1970) J Biol Chem , vol.245 , pp. 5228-5233
    • Elford, H.L.1    Freese, M.2    Passamani, E.3    Morris, H.P.4
  • 36
    • 33751169387 scopus 로고    scopus 로고
    • Hypoxia-inducible factor-1 (HIF-1)
    • Q. Ke, and M. Costa Hypoxia-inducible factor-1 (HIF-1) Mol Pharmacol 70 2006 1469 1480
    • (2006) Mol Pharmacol , vol.70 , pp. 1469-1480
    • Ke, Q.1    Costa, M.2
  • 37
    • 0036897079 scopus 로고    scopus 로고
    • A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines
    • T.W. Chong, L.D. Horwitz, J.W. Moore, H.M. Sowter, and A.L. Harris A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines Cancer Res 62 2002 6924 6927 (Pubitemid 35424082)
    • (2002) Cancer Research , vol.62 , Issue.23 , pp. 6924-6927
    • Wen Chong, T.1    Horwitz, L.D.2    Moore, J.W.3    Sowter, H.M.4    Harris, A.L.5
  • 38
    • 50849085751 scopus 로고    scopus 로고
    • The iron-regulated metastasis suppressor. Ndrg-1: Identification of novel molecular targets
    • Z. Kovacevic, D. Fu, and D.R. Richardson The iron-regulated metastasis suppressor. Ndrg-1: identification of novel molecular targets Biochim Biophys Acta 1783 2008 1981 1992
    • (2008) Biochim Biophys Acta , vol.1783 , pp. 1981-1992
    • Kovacevic, Z.1    Fu, D.2    Richardson, D.R.3
  • 39
    • 34247373460 scopus 로고    scopus 로고
    • Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression
    • DOI 10.1182/blood-2006-10-047753
    • E. Nurtjahja-Tjendraputra, D. Fu, J.M. Phang, and D.R. Richardson Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression Blood 109 2007 4045 4054 (Pubitemid 46641760)
    • (2007) Blood , vol.109 , Issue.9 , pp. 4045-4054
    • Nurtjahja-Tjendraputra, E.1    Fu, D.2    Phang, J.M.3    Richardson, D.R.4
  • 40
    • 34548286520 scopus 로고    scopus 로고
    • Tuning cell cycle regulation with an iron key
    • Y. Yu, Z. Kovacevic, and D.R. Richardson Tuning cell cycle regulation with an iron key Cell Cycle 6 2007 1982 1994 (Pubitemid 47327885)
    • (2007) Cell Cycle , vol.6 , Issue.16 , pp. 1982-1994
    • Yu, Y.1    Kovacevic, Z.2    Richardson, D.R.3
  • 41
    • 0029066979 scopus 로고
    • Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary results. Italian Neuroblastoma Cooperative Group
    • A. Donfrancesco, B. De Bernardi, M. Carli, A. Mancini, M. Nigro, and L. De Sio Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group Eur J Cancer 31A 1995 612 615
    • (1995) Eur J Cancer , vol.31 , pp. 612-615
    • Donfrancesco, A.1    De Bernardi, B.2    Carli, M.3    Mancini, A.4    Nigro, M.5    De Sio, L.6
  • 43
    • 0037237032 scopus 로고    scopus 로고
    • Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311
    • T.B. Chaston, D.B. Lovejoy, R.N. Watts, and D.R. Richardson Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311 Clin Cancer Res 9 2003 402 414 (Pubitemid 36109758)
    • (2003) Clinical Cancer Research , vol.9 , Issue.1 , pp. 402-414
    • Chaston, T.B.1    Lovejoy, D.B.2    Watts, R.N.3    Richardson, D.R.4
  • 44
    • 0033975268 scopus 로고    scopus 로고
    • Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
    • DOI 10.1016/S0006-2952(99)00419-0, PII S0006295299004190
    • R.A. Finch, M. Liu, S.P. Grill, W.C. Rose, R. Loomis, and K.M. Vasquez Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 2000 983 991 (Pubitemid 30110814)
    • (2000) Biochemical Pharmacology , vol.59 , Issue.8 , pp. 983-991
    • Finch, R.A.1    Liu, M.-C.2    Grill, S.P.3    Rose, W.C.4    Loomis, R.5    Vasquez, K.M.6    Cheng, Y.-C.7    Sartorelli, A.C.8
  • 45
    • 33645473324 scopus 로고    scopus 로고
    • A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase
    • J. Shao, B. Zhou, A.J. Di Bilio, L. Zhu, T. Wang, and C. Qi A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase Mol Cancer Ther 5 2006 586 592
    • (2006) Mol Cancer Ther , vol.5 , pp. 586-592
    • Shao, J.1    Zhou, B.2    Di Bilio, A.J.3    Zhu, L.4    Wang, T.5    Qi, C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.